A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers
Completed · Phase 1
Conditions studied: Drug-Drug Interaction Healthy Volunteers
In brief
The primary aim of this Phase 1 study is to evaluate the effect of vapendavir daily doses of 528 mg daily (QD) and 264 mg twice daily (BID) on the pharmacokinetic (PK) profile of midazolam, a cytochrome (CYP) 3A4 substrate. Additionally, the effect of midazolam on the PK profile of vapendavir, a PK profile comparison of vapendavir in males and females, as well as the safety of vapendavir will also be assessed.
Key facts
- Study ID
- NCT02204501
- Run by
- Biota Scientific Management Pty Ltd
- People needed
- 24
- Starts
- 2014-05-01
- Expected to finish
- 2014-06-01
- Last updated by the study team
- 2018-05-30
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Must be male or female between 18 and 55 years of age (inclusive) with BMI between 18 and 30 kg/m2 (inclusive), and weight ≥50 kg at the time of screening;
- Capable of giving written informed consent;
- Subject is able to understand and comply with the protocol requirements, instructions and restrictions;
- Healthy on the basis of physical examination, medical history, medication usage, vital signs (VS), electrocardiograms (ECGs), and clinical laboratory tests;
- Female subjects who are not post-menopausal for at least 2 years or surgically sterile with complete hysterectomy or bilateral oophorectomy and male subjects who are not surgically sterile via vasectomy, must agree to use a double barrier method of birth control, such as a condom plus spermicidal agent (foam/gel/film/cream/suppository); and
- Female subjects must not be breastfeeding or pregnant.
You may not qualify if…
- Positive results for Hepatitis B, Hepatitis C, or HIV;
- Frequent use (defined as > 5 times/day) of tobacco products, including cigarettes, cigars, chewing tobacco;
- A medical history of significant hematological, gastrointestinal, respiratory, renal, hepatic, cerebrovascular, immunologic, psychiatric or cardiovascular disease or event;
- Current or recent respiratory infection (defined as within 14 days of first study visit participation)
- Presence or history of significant allergy;
- Clinically significant abnormalities noted on ECG;
- Screening vital signs representing sustained elevated systolic blood pressure <90 mmHg or >140 mmHg, and/or diastolic blood pressure <55 mmHg or >90 mmHg.
- Presence of significant gastrointestinal abnormalities such as diarrhea or constipation;
- Safety laboratory abnormalities noted at screening which are clinically significant
- Current or defined history of abuse of alcohol or illicit drugs;
- A positive pregnancy test at screening;
- Poor vein access or fear of venipuncture or sight of blood; and
- Regular consumption of alcohol defined as either > 2 units (glass or shot) of alcoholic beverages per day or > 14 units per week.
Where it is running
- Prism Clinical Research — Saint Paul, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.